Viewing Study NCT05123703


Ignite Creation Date: 2025-12-24 @ 7:36 PM
Ignite Modification Date: 2026-01-01 @ 10:35 PM
Study NCT ID: NCT05123703
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-22
First Post: 2021-11-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module